The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Treating R/R DLBCL in 2025: CAR T-cell therapy and bispecific antibodies
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the various treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). He highlights the importance of considering CAR T-cell therapy as a curative intent strategy, and notes that other options, such as bispecific antibodies, are emerging for those who do not have access to CAR-T. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
